semaj83/ctmatch_classification huggingface dataset:
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 3.0-14.0,  Growth Hormone Deficiency Idiopathic Short Stature Small for Gestational Age Prepubertal patients Male/female Ages 3-14 yrs Being treated with growth hormone for the conditions of growth hormone deficiency, idiopathic short stature, and small-for-gestational age with failure to catch up to the normal growth curve by age 2 years  Patients being treated with growth hormone for other conditions such as Turner syndrome, chronic renal failure, or Prader-Willi syndrome
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Breast Cancer Diagnosis of breast cancer T2-T4c, any N, M0 disease Clinically staged, as documented by the treating physician, as 1 of the following T4a-c disease for which modified radical mastectomy with negative margins is the goal T2 or T3 disease for which conversion from needing mastectomy to breast conservation is the goal T2 disease for which lumpectomy at first attempt is the goal Primary tumor must be palpable and measure > 2 cm by tape, ruler, or caliper measurements in at least one dimension Must agree to undergo mastectomy or lumpectomy after neoadjuvant aromatase inhibitor therapy No inflammatory breast cancer, defined as clinically significant erythema of the breast and/or documented dermal lymphatic invasion (not direct skin invasion by tumor or peau d'orange without erythema) No distant metastasis (M1)
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 4.0-20.0,  Turner Syndrome Previously randomized in study B9R-US-GDFG (NCT00406926) Karyotype-proven Turner syndrome  Immediate family members of study site personnel directly affiliated with the study
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 4.0-999.0,  Glaucoma Subjects with the following will be recruited: 1. Individuals or family members of individuals with glaucoma, either congenital, childhood, or age related. 2. Adults must be capable of providing their own consent. 3. All subjects must be able to cooperate with study examination and phlebotomy. 4. Older than 4 years of age  Diseases, infections, or trauma that mimic primary glaucoma. 2. Children requiring sedation for study procedures
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 2.0-999.0,  Infections, Meningococcal Subjects who the investigator believes that they and/or their parent/guardian can and will comply with the requirements of the protocol A Filipino male or female > 2 years of age at the time of the first vaccination Free of obvious health problems as established by medical history and clinical examination before entering into the study Written informed consent obtained from the subject and/or from the parent/ guardian of the subject  Subjects suffering from acute severe febrile illness History of allergic disease or reactions likely to be exacerbated by any component of the vaccine Major congenital defects or serious chronic illness History of any neurologic disorders or seizures Pregnant or lactating female Female planning to become pregnant History of chronic alcohol consumption and/or intravenous drug abuse Any contraindications as stated on the Prescribing Information
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Breast Neoplasms Fibrocystic Disease of Breast Mammaplasty first visit to a Breast Disease Ambulance for consultation no pregnancy  no severe heart disease (EF > 40%) no therapy with digitalis no acute/chronic inflammatory disease (e.g. RA, M. Crohn) no dysfunction of the Hypothalamo-Pituitary-Adrenal system no severe mental disorder
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 8.0-14.25,  Idiopathic Short Stature (ISS) male or female children with ISS age greater than or equal to 8 years and less than or equal to 12 years and 3 months for girls and greater than or equal to 9 years and less than or equal to 14 years and 3 months for boys bone age less than or equal to 12.0 years for girls and less than or equal to 14.0 years for boys based on a central reading of an X-ray of the left hand and wrist Pubertal stage B2 and B3 for girls based on the Tanner method Pubertal stage G2 and G3 for boys based on the Tanner method  Growth hormone deficiency (GHD) Insulin-like growth factor-I levels greater than 3 SDS Chromosomal abnormality diagnosed locally on a karyotype. For girls, the karyotype to eliminate a Turner syndrome, is mandatory Small for gestational age (SGA) Has reached menarche (had her first menstrual period) Have any significant concomitant disease that is likely to interfere with growth or with the study, or is a known contraindication to Growth Hormone treatment
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 10.0-75.0,  Chronic Myelogenous Leukemia Acute Myelogenous Leukemia Chronic Lymphocytic Leukemia Acute Lymphoblastic Leukemia Myelodysplastic Syndrome Ages 10-75 years inclusive Chronic myelogenous leukemia (CML) Subjects under the age of 21 in chronic phase Subjects ages 10-75 in chronic phase who have failed treatment with imatinib, have intolerance to imatinib, or who did not receive imatinib at therapeutic doses within the first 12 months from diagnosis Subjects ages 10-75 in accelerated phase or blast transformation Acute lymphoblastic leukemia (ALL): any of these categories: ALL in first remission with high-risk features (presenting leukocyte count greater than 100,000/cu mm, Karyotypes t9; 22, t4, t19, t11, biphenotypic leukemia) All second or subsequent remissions, primary induction failure, partially responding or untreated relapse Acute myelogenous leukemia (AML): AML in first remission except AML with good risk karyotypes: AML M3 (t15; 17), AML M4Eo (inv 16), AML t (8; 21). All AML in second or subsequent remission, primary induction failure and resistant relapse Myelodysplastic syndromes (MDS): any of these categories refractory anemia with transfusion dependence, refractory anemia with excess of blasts, transformation to acute leukemia, chronic myelomonocytic leukemia, atypical MDS/myeloproliferative syndromes  Estimated probability of surviving less than three months Major anticipated illness or organ failure incompatible with survival from transplant Severe psychiatric illness. Mental deficiency sufficiently severe as to make compliance with the transplant treatment unlikely and making informed consent impossible Positive pregnancy test for women of childbearing age HIV positive DLCO adjusted for ventilation and hemoglobin less than 65 percent predicted Left ventricular ejection fraction less than 40 percent AST/SGOT greater than 10 times ULN (CTCAE grade IV v3.0) Bilirubin greater than 5 times ULN (CTCAE grade IV v3.0) Creatinine greater than 4.5 times ULN (CTCAE grade IV v 3.0)
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Systemic Lupus Erythematosus Eligible women will be those having any two of the following 1. Amenorrhea of 6 months or more. 2. Serum follicle-stimulating hormone level of 30 IU/L or more. 3. Menopausal symptoms. 4. Age 48 years or older  Women older than 65 years. 2. Severe lupus activity at baseline (SLEDAI score, more than 30). 3. Use of estrogens within 3 months of the screening visit. 4. Serum creatinine of 2.0 mg/dL or more. 5. Hypertriglyceridemia 500 mg/dL or more. 6. Metabolic bone diseases. 7. Liver disease. 8. Untreated hyperthyroidism. 9. Recent thrombosis. 10. Malignancy. 11. Endometrial hyperplasia. 12. Undiagnosed uterine bleeding or cervical dysplasia
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.75-4.0,  Turner Syndrome Karyotype-proven Turner syndrome that included a documented abnormality of the short arm of an X chromosome At least 9 months of age and not greater than 4 years of age Normal values for age for hemoglobin, thyroid stimulating hormone (TSH) and urinalysis (office dipstick is adequate), performed prior to study entry If there was a known history of hypothyroidism, then adequate thyroid hormone replacement must have been taken for at least 6 months prior to study entry  Current or previous treatment with any therapy that may have directly influenced growth, including growth hormone, growth hormone-releasing hormone, estrogens and anabolic steroids such as oxandrolone. This included previous completion of, or withdrawal from, this study or any other study investigating therapeutic uses of growth hormone or growth hormone-releasing hormone Chronic treatment with systemic glucocorticoids in supra-physiological doses Treatment with potential growth-influencing medications such as methylphenidate (Ritalin), pemoline (Cylert), and amphetamines, at, or within 3 months prior to, study entry Presence of any Y chromosome component in the karyotype if gonads were in situ. Subjects whose karyotype contained Y chromatin, but who had undergone gonadectomy, were eligible to enter the study Presence of any additional known autosomal abnormality
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 10.0-18.0,  Attention Deficit Hyperactivity Disorder Community-based sample for the development of several Chinese versions of instruments: SNAP-IV, SDQ, ASRI, and ASRS ADHD follow-up family studies (ADHD group): (1) that subjects either had the clinical diagnosis of DSM-IV ADHD, which was made by a full-time child psychiatrist at the first visit and following visits or by a child psychiatrist using the K-SADS-E as the second-stage case ascertainment at an epidemiological study; (2) the diagnoses of ADHD were made 3-6 years ago; (3) their ages range from 12 to 15 when we conduct study; (4) subjects have at least one sibling aged 6-18 and live with at least one biological parent; and (5) subjects and their family consent to participate in this study (control group)(1) that subjects were assessed either at a clinical setting or in an epidemiological study same as to those in the exposed group 6 years ago; (2) their ages range from 12 to 15 when we conduct study; (3) subjects have at least one sibling aged 6-18 and live with at least one biological parent; and (4) subjects and their family consent to participate in this study  The subjects, including those who in the exposed and unexposed groups, will be excluded from the study if they currently meet or have a history of the following condition as defined by DSM-IV: Schizophrenia, Schizoaffective Disorder, Organic Psychosis, Mental Retardation, or Pervasive Developmental Disorder. Moreover, the subjects will be excluded from the unexposed group if have a history of the following condition as defined by DSM-IV: ADHD, ODD, or CD in addition to the above
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 20.0-40.0,  Turner Syndrome Turner syndrome Age 20-40  Symptomatic heart disease Anti hypertensive treatment Untreated thyroid disease Adipositas (BMI > 35) Treatment with glucocorticoids Pregnancy
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Osteoarthritis Arthralgia Osteoarthritis of the knee Persistent osteoarthritic symptoms for at least 6 months Radiographic evidence of late stage osteoarthritis of the knee (stage III-IV) History of conservative management including pain medication and physical therapy  Anticoagulant treatment or history of hemophilia History or presence of rheumatic diseases leading to secondary osteoarthritis Presence of hematological, hepatic, renal or immunological disease Insulin-dependant diabetes mellitus Intraarticular injections or systemic application of corticosteroids during the 3 preceding months History of surgery of the affected knee during the last 3 months or joint replacement History of previous leech therapy Lack of informed consent
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 3.167-14.0,  Turner Syndrome Short Stature Turner syndrome defined by a structural aberration or lack of the X chromosome Growth velocity less than 2 cm/year at the time of final analysis (= final height)  Age <3.5 or >14 years at start of GH therapy GH peak serum levels < 8 ng/ml in two independent tests Thelarche at start or during the first year of treatment Oxandrolone therapy for any time and a duration of GH therapy less than 2 years
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 1.0-81.0,  Growth Hormone Deficiency Patient with growth hormone deficiency
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 40.0-75.0,  Diabetes Mellitus Hypertension Men or women of any racial background Age >= 40 years and <= 75 years SBP>= 130 mmHg and < 140 mmHg or DBP >= 85 mmHg and < 90 mmHg, average of screening and randomisation visits (in absence of any antihypertensive medication) FG >=100 mg/dl (5.6 mmol/l) and < 126 mg/dl (7.0 mmol/l) between screening and randomisation (in absence of any antidiabetic medication) Waist circumference >= 102 cm in men and >= 88 cm in women  SBP >= 140 mmHg or DBP >= 90 mmHg Any antihypertensive, antidiabetic or antiobesity medication at the time of or during the 6 months previous to randomisation Any current or previous cardiovascular or renal disease requiring continuous administration of Ds, ßBs, ACEIs, ARBs, CAs, and any other antihypertensive medication Any medical condition preventing adherence to lifestyle measures included in the protocol Hepatic disease as AST (SGOT) or ALT (SGPT) values equal or greater than two times the upper limit of normal Chronic renal dysfunction as serum creatinine > 2.0 mg/dl Any gastrointestinal disorder interfering with drug absorption Known allergy or contraindications to ACEIs or ARBs Pregnant or lactating women; women in reproductive age not using recognized contraceptive methods Malignancy within the last 5 years
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 12.0-65.0,  Mental Retardation mentally retarded persons ages 12 to 65 undergoing dental rehabilitation  patients who are pregnant parents/and or legal guardians who do not wish to give consent
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.083-21.0,  Cerebral Palsy Weakness Hypertonia weakness, hypertonia, or hyperkinetic disorder affecting one or both arms reduced speed or quality of reaching  any condition that would increase the risk of participation